356
Participants
Start Date
April 19, 2023
Primary Completion Date
December 1, 2025
Study Completion Date
October 30, 2026
SKB264
intravenous (IV) infusion (Q2W or Q3W)
Pembrolizumab
intravenous (IV) infusion (400mg, Q6W)
Carboplatin
intravenous (IV) infusion (AUC5, Q3W)
Osimertinib
80mg, QD
Samsung Medical Center, Seoul
Seoul National University Bundang Hospital, Seongnam-si
The Catholic University of Korea, St. Vincent's Hospital, Suwon
Hospital Universitario Puerta De Hierro De Majadahonda, Majadahonda
Hospital Universitario QuirónSalud Madrid, Pozuelo de Alarcón
Chungbuk National University Hospital, Cheongju-si
Hospital Quironsalud Malaga, Málaga
Shanxi Provincial Cancer Hospital, Taiyuan
Hospital Universitario Virgen de Valme, Seville
Inonu University Turgut Ozal Medical Center, Malatya
Henan Cancer Hospital,Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou
Hospital Clinico Universitario De Valencia, Valencia
Inje University Haeundae Paik Hospital, Busan
Beijing Cancer Hospital, Beijing
The First Hospital of Chinese Medical University(Heping Compus), Shenyang
Jilin Cancer Hospital, Changchun
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai Chest Hospital, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Shanghai East Hospital, Shanghai
Centrul de Oncologie Sf. Nectarie, Craiova
Shandong Cancer Hospital and Institute, Jinan
Tianjin Medical University Cancer Institute & Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital of Nanchang University, Nanchang
Jiangxi Cancer Hospital, Nanchang
Fujian Cancer Hospital, Fuzhou
Chongqing University Cancer Hospital (Chongqing Cancer Hospital), Chongqing
Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, Cluj-Napoca
Medisprof, Cluj-Napoca
Hunan Cancer Hospital, Changsha
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Zhongnan Hospital of Wuhan University, Wuhan
Hubei Cancer Hospital, Wuhan
The First Affiliated Hospital of Zhengzhou University(Heyi Compus), Zhengzhou
Sun Yat-Sen University Cancer Center, Guangzhou
Sun Yatsen University Cancer Center Huangpu Hos, Guangzhou
Guangxi Cancer Hospital/ Guangxi Medical University Cancer Hospital, Nanning
Sichuan Cancer Hospital, Chengdu
West China Hospital of Sichuan University, Chengdu
Chengdu Fifth People's Hospital, Chengdu
Yunnan Cancer Hospital,The Third Affiliated Hospital of Kunming Medical University ,Yunnan Cancer Center, Kunming
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
ISR-GEO Med Res Clin Healthycore, Tbilisi
"LLC Todua Clinic", Tbilisi
Ltd New Hospitals, Tbilisi
Tbilisi St Med U Ingorokva High Med, Tbilisi
LTD Institute of Clinical Oncology, Tbilisi
Severance Hospital, Yonsei University Health System, Seoul
Micancer Center S.L.P., Barcelona
Hospital Universitari Dexeus Grupo Quironsalud, Barcelona
Hospital Universitari Vall D Hebron, Barcelona
Medical Park Seyhan Hospital, Adana
Adana City Training and Research Hospital, Adana
Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi, Ankara
Hacettepe University Medical Faculty, Ankara
Gazi University Medical Faculty, Ankara
Ankara Liv Hospital Tibbi Onkoloji, Ankara
Lead Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
INDUSTRY
Klus Pharma Inc.
INDUSTRY